NeoGenomics (NASDAQ:NEO - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, April 29th. Analysts expect NeoGenomics to post earnings of ($0.02) per share and revenue of $171.38 million for the quarter.
NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). The firm had revenue of $172.00 million during the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. On average, analysts expect NeoGenomics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NeoGenomics Price Performance
Shares of NASDAQ NEO traded up $0.18 during midday trading on Friday, reaching $10.27. 1,432,237 shares of the stock traded hands, compared to its average volume of 966,356. The stock has a market capitalization of $1.32 billion, a PE ratio of -16.56 and a beta of 1.41. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The company's 50 day moving average is $9.80 and its 200 day moving average is $13.47. NeoGenomics has a one year low of $8.05 and a one year high of $19.12.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on NEO shares. The Goldman Sachs Group reduced their price objective on shares of NeoGenomics from $17.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Bank of America cut their price target on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. Piper Sandler decreased their target price on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Benchmark downgraded NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. Finally, Needham & Company LLC lowered their price objective on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $19.30.
Read Our Latest Report on NeoGenomics
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
